Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021
Go back to Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021| CELLDEX THERAPEUTICS, Inc. (NASDAQ: CLDX) | Delayed: 38.98 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $38.98 | 52 Week High | $18.62 | |||
| Open | $38.98 | 52 Week Low | $2.85 | |||
| Day High | $38.98 | P/E | N/A | |||
| Day Low | $38.98 | EPS | $-1.02 | |||
| Volume | 1,577 | |||||
